Weight Management

New oral GLP-1 agonist orforglipron cuts A1C and drives meaningful weight loss in trials, offering easier dosing than injections.

GoodRx enhances access to semaglutide with affordable cash pricing, revolutionizing obesity treatment and supporting patients in weight management.

Orforglipron shows promise in maintaining weight loss for individuals transitioning from injectable therapies, offering a convenient oral option for obesity management.

The FDA approved the first oral GLP-1 pill for weight management, offering a convenient alternative for obesity treatment and enhancing patient access.

Retatrutide shows promising results in reducing weight and knee pain for individuals with obesity and osteoarthritis, enhancing physical function significantly.

Pharmacists debate the effectiveness and ethics of GLP-1 agonists for pediatric obesity, highlighting the need for balanced treatment approaches.

Pharmacy leaders navigate complex compliance challenges, budget constraints, and evolving technology to enhance safety and efficiency in compounding practices.

GLP-1 receptor agonists expand treatment options for diabetes, weight loss, and more, showing promise in heart failure, kidney disease, and neuroprotection.

Diana Isaacs, PharmD, discusses evolving perceptions of obesity, the expanding role of pharmacotherapy, and how pharmacists can drive access, counseling, and long-term metabolic health.

The 1-year extension period in trials will be discontinued based on the efficacy results observed in the overall study population, said Novo Nordisk.

Plozasiran gains FDA approval to significantly lower triglycerides in adults with familial chylomicronemia syndrome, enhancing heart health management.

Semaglutide shows significant weight loss and reduces obesity-related health risks, offering a promising solution for effective weight management.

The move continues the push towards most favored nation (MFN) status, lowering the prices of glucagon-like peptide-1 (GLP-1s) drugs for Medicare recipients.

Oral semaglutide shows promise in enhancing glucose control and reducing cardiovascular risks.

Berberine is increasingly used for weight management despite limited supporting evidence, emphasizing the need for pharmacist-led education, interaction monitoring, and adverse effect counseling.

Recent research reveals rising cancer rates among younger and older adults, linking obesity to increased incidence.

Lawmakers weigh cost concerns, clinical outcomes, and regulatory barriers as access to these medications evolves.

The FDA's approval of GLP-1 for obstructive sleep apnea enhances treatment options, emphasizing pharmacists' vital role in patient care and management.

Pharmacists are uniquely positioned to help prevent nutritional deficiencies, manage adverse effects, and maintain long-term health through tailored guidance.

GLP-1 receptor agonists show potential as innovative treatments for alcohol and substance use disorders, addressing critical public health needs.

GLP-1 receptor agonists significantly influence FDG-PET-CT scan interpretations, potentially leading to misdiagnosis in cancer detection.

Cagrilintide shows significant weight loss in adults with obesity, marking a breakthrough in obesity treatment with promising phase 3 trial results.

Metabolic bariatric surgery offers greater weight loss and lower costs than GLP-1 treatments for obesity, prompting a reevaluation of treatment strategies.